atai Life Sciences

atai Life Sciences is one of the biggest companies in the psychedelics field. The company aims to be a platform and has nine subsidiary companies working on everything from psilocybin for depression to DMT administration.

atai Life Sciences

“atai Life Sciences AG is a global biotechnology company builder that aims to ultimately cure mental health disorders. atai leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental illness. In particular, atai is committed to developing psychedelic substances to address significant unmet medical needs that are rooted in a lack of innovation in neuropsychiatry. Investors include Christian Angermayer, Mike Novogratz, Thor Bjorgolfsson, and Subversive Capital, among others.”

Company Information

atai Life Sciences Website

January, 2018


B2B B2C Conglomerate / Platform Pharmaceutical Biotech Drug Discovery

Compounds of Interest
Psilocybin MDMA Ibogaine Ketamine

Topics of Interest

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships

Company News

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD (atai Life Sciences, 12 October 2022)
atai Life Sciences has announced positive initial results for their Phase I clinical trial of KUR-101

Drug companies are investing big in psychedelics, but can they engineer out the trip? (Chemical & Engineering News, 06 March 2022)

Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They? (Psychedelic Spotlight, 21 April 2022)

atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine (Yahoo Finance, 16 February 2022)
atai Impact, the philanthropic program of atai Life Sciences and the Multidisciplinary Association for Psychedelic Studies (MAPS) today announced a $500,000 donation from atai Impact to MAPS.

H.C. Wainwright Stick to Their Buy Rating for ATAI Life Sciences (, 22 November 2021)

atai Life Sciences increases its ownership position in COMPASS Pathways (, 29 November 2021)


HQ / Office Berlin, Germany